AcceleRET Lung, an ongoing phase III study, will evaluate the efficacy and safety of pralsetinib versus standard of care for first-line treatment of advanced/metastatic RET fusion-positive NSCLC (ClinicalTrials.gov Identifier: NCT04222972). The gene discussed is RET; the disease is non-small cell lung carcinoma.